Last reviewed · How we verify
DPP-4 inhibitors
DPP-4 inhibitors is a Small molecule drug developed by Novo Nordisk A/S. It is currently FDA-approved. Also known as: incretin-based drugs, sitagliptin, vildagliptin, saxagliptin.
DPP-4 inhibitors, marketed by Novo Nordisk A/S, hold a significant position in the diabetes management market. The key composition patent is set to expire in 2028, providing a strong competitive advantage until then. The primary risk is the potential increase in competition post-patent expiry.
At a glance
| Generic name | DPP-4 inhibitors |
|---|---|
| Also known as | incretin-based drugs, sitagliptin, vildagliptin, saxagliptin, Sitagliptin |
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Cofrogliptin on Beta-Cell Function in LADA Patients (NA)
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (PHASE4)
- Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
- Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients
- Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis (PHASE4)
- Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC (PHASE4)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DPP-4 inhibitors CI brief — competitive landscape report
- DPP-4 inhibitors updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI
Frequently asked questions about DPP-4 inhibitors
What is DPP-4 inhibitors?
Who makes DPP-4 inhibitors?
Is DPP-4 inhibitors also known as anything else?
What development phase is DPP-4 inhibitors in?
Related
- Manufacturer: Novo Nordisk A/S — full pipeline
- Also known as: incretin-based drugs, sitagliptin, vildagliptin, saxagliptin, Sitagliptin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing